Clinical Trials Browser

Completed × dabrafenib × Endocrine × Clear all

Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation

NCT01723202 2025-08-24

Dabrafenib With or Without Trametinib in Treating Patients With Advanced Differentiated Thyroid Cancer

Phase 2 Completed

53 enrolled 11 charts

EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

NCT02034110 2023-08-21

Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers

Phase 2 Completed

206 enrolled 40 charts 2 FDA

CNSEndocrineGastrointestinalHead & NeckOther hematologic neoplasmPlasma cellSarcoma

Nonseminomatous germ cell tumor, Biliary Tract Neoplasms, Glioma, Leukemia, Hairy Cell, Multiple Myeloma, Neoplasms, Gastrointestinal Stromal Tumors, Thyroid Carcinoma, Anaplastic

NCT01534897 2017-03-15

Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436

Phase NA Completed

10 enrolled 9 charts

EndocrineHead & Neck

Thyroid Cancer, Papillary, Neoplasm Metastasis, Thyroid Neoplasms

Clinical Trials

MERAIODE

Dabrafenib With or Without Trametinib in Treating Patients With Advanced Differentiated Thyroid Cancer

Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers

Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436